Evaxion A/S has announced the successful completion of an at-the-market offering, raising approximately $775,068 through the sale of American Depositary Shares (ADSs). This move is significant for the company as it aims to strengthen its financial position and support its ongoing projects in the biological products sector.

During the period between October 19 and October 21, 2026, Evaxion sold a total of 201,198 ADSs, which represent the company’s ordinary shares. The sales were executed at varying average prices, with the highest being $4.4222 per ADS. This capital infusion is expected to bolster Evaxion's operations and enhance its capacity to innovate in the field of biological products.

Background

Evaxion A/S, classified under the SIC code 2836, specializes in biological products, excluding diagnostic substances. The company is publicly traded on the Nasdaq under the ticker symbol EVAX. Evaxion has been active in the market, with several recent filings, including multiple 6-K forms leading up to this capital raise.

What the Filing Says

The recent filing details the ADS sales, stating, "During the period between October 19, 2026 and October 21, 2026, the Company sold an aggregate of 201,198 American Depositary Shares... at an average price of USD $3.9714 per ADS." The filing also highlights the net proceeds after deducting fees and expenses, amounting to approximately $775,068.

Impact

This capital raise may positively affect Evaxion's growth trajectory, enabling it to invest in research and development, as well as operational enhancements. The funds raised will likely allow the company to advance its projects in the biological products sector, positioning it competitively against other firms in the industry.

What's Next

The filing does not specify what happens next, but the increased capital could lead to further developments or announcements regarding Evaxion's product pipeline and strategic initiatives.